secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001628280-25-024067
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner
--------------------------------------------------------------------------------

- HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.
- No global development partner secured for chronic HBV; Phase 3 will not proceed.
- Company to streamline final stages of MARCH Phase 2, focusing on hepatitis delta ECLIPSE Phase 3 and T-cell engager oncology programs.
- Cash runway guidance into mid-2027 reaffirmed based on current operating plan.
- Safety profile consistent; no new concerns; generally mild/moderate adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025024067/0001628280-25-024067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025024067/vir-20250509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-024067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer